Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE4.1500
- TODAY'S CHANGE (%)0.0600 (1.4670%)
- Bid / Lots3.9100/ 5
- Ask / Lots4.3000/ 1
- Open / Previous Close4.1800 / 4.0900
- Day Range
- 52 Week Range
- Volume200,009
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 8695 | 4.11 |
| 09:38 ET | 427 | 4.15 |
| 09:43 ET | 832 | 4.17 |
| 09:45 ET | 606 | 4.1804 |
| 09:48 ET | 100 | 4.18 |
| 09:50 ET | 1600 | 4.16 |
| 09:54 ET | 1008 | 4.1504 |
| 09:56 ET | 308 | 4.2 |
| 09:59 ET | 639 | 4.185 |
| 10:01 ET | 1000 | 4.1887 |
| 10:03 ET | 1073 | 4.1961 |
| 10:06 ET | 300 | 4.1925 |
| 10:08 ET | 2500 | 4.19 |
| 10:10 ET | 1300 | 4.18 |
| 10:12 ET | 738 | 4.19 |
| 10:14 ET | 300 | 4.18 |
| 10:15 ET | 450 | 4.18 |
| 10:19 ET | 1211 | 4.15 |
| 10:21 ET | 3593 | 4.11 |
| 10:26 ET | 557 | 4.13 |
| 10:28 ET | 4463 | 4.17 |
| 10:30 ET | 1600 | 4.1601 |
| 10:32 ET | 5976 | 4.11 |
| 10:33 ET | 1200 | 4.1399 |
| 10:35 ET | 198 | 4.126 |
| 10:37 ET | 100 | 4.11 |
| 10:39 ET | 3814 | 4.12 |
| 10:42 ET | 100 | 4.14 |
| 10:46 ET | 589 | 4.14 |
| 10:48 ET | 2000 | 4.12 |
| 10:50 ET | 900 | 4.115 |
| 10:51 ET | 800 | 4.09 |
| 10:53 ET | 500 | 4.11 |
| 10:55 ET | 607 | 4.105 |
| 11:11 ET | 1748 | 4.12 |
| 11:15 ET | 400 | 4.12 |
| 11:18 ET | 200 | 4.12 |
| 11:20 ET | 100 | 4.12 |
| 11:24 ET | 1550 | 4.14 |
| 11:38 ET | 518 | 4.17 |
| 11:42 ET | 228 | 4.17 |
| 11:45 ET | 181 | 4.1503 |
| 11:47 ET | 100 | 4.165 |
| 11:49 ET | 950 | 4.16 |
| 11:51 ET | 914 | 4.15 |
| 11:54 ET | 300 | 4.14 |
| 11:56 ET | 175 | 4.14 |
| 11:58 ET | 100 | 4.15 |
| 12:00 ET | 100 | 4.15 |
| 12:02 ET | 500 | 4.16 |
| 12:12 ET | 856 | 4.15 |
| 12:16 ET | 2000 | 4.15 |
| 12:18 ET | 900 | 4.15 |
| 12:20 ET | 174 | 4.14 |
| 12:27 ET | 100 | 4.13 |
| 12:32 ET | 908 | 4.13 |
| 12:38 ET | 1398 | 4.111 |
| 12:39 ET | 400 | 4.1 |
| 12:41 ET | 500 | 4.09 |
| 12:43 ET | 1545 | 4.09 |
| 12:45 ET | 100 | 4.09 |
| 12:48 ET | 100 | 4.09 |
| 12:50 ET | 300 | 4.11 |
| 12:52 ET | 336 | 4.1 |
| 12:54 ET | 200 | 4.1 |
| 12:56 ET | 500 | 4.11 |
| 12:59 ET | 600 | 4.12 |
| 01:10 ET | 100 | 4.12 |
| 01:24 ET | 250 | 4.1101 |
| 01:28 ET | 100 | 4.1157 |
| 01:30 ET | 1387 | 4.12 |
| 01:32 ET | 200 | 4.12 |
| 01:35 ET | 1383 | 4.11 |
| 01:37 ET | 1649 | 4.09 |
| 01:44 ET | 122 | 4.11 |
| 01:46 ET | 200 | 4.095 |
| 01:50 ET | 342 | 4.095 |
| 01:51 ET | 300 | 4.095 |
| 01:57 ET | 100 | 4.095 |
| 02:02 ET | 1100 | 4.09 |
| 02:04 ET | 100 | 4.09 |
| 02:08 ET | 100 | 4.1 |
| 02:09 ET | 499 | 4.1 |
| 02:11 ET | 2262 | 4.13 |
| 02:13 ET | 752 | 4.11 |
| 02:15 ET | 100 | 4.11 |
| 02:18 ET | 100 | 4.11 |
| 02:20 ET | 100 | 4.1 |
| 02:24 ET | 1246 | 4.1 |
| 02:27 ET | 100 | 4.11 |
| 02:36 ET | 325 | 4.1 |
| 02:42 ET | 500 | 4.11 |
| 02:47 ET | 1094 | 4.12 |
| 02:49 ET | 400 | 4.13 |
| 02:51 ET | 1300 | 4.14 |
| 03:07 ET | 200 | 4.13 |
| 03:12 ET | 246 | 4.1384 |
| 03:14 ET | 2386 | 4.15 |
| 03:16 ET | 1107 | 4.12 |
| 03:18 ET | 607 | 4.1246 |
| 03:25 ET | 200 | 4.13 |
| 03:27 ET | 1467 | 4.135 |
| 03:30 ET | 1183 | 4.1391 |
| 03:32 ET | 1600 | 4.135 |
| 03:34 ET | 641 | 4.12 |
| 03:38 ET | 200 | 4.13 |
| 03:39 ET | 300 | 4.13 |
| 03:43 ET | 6648 | 4.16 |
| 03:45 ET | 1571 | 4.16 |
| 03:48 ET | 752 | 4.1679 |
| 03:50 ET | 200 | 4.17 |
| 03:52 ET | 5621 | 4.18 |
| 03:54 ET | 500 | 4.17 |
| 03:56 ET | 4656 | 4.155 |
| 03:57 ET | 13744 | 4.13 |
| 03:59 ET | 28064 | 4.15 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 243.0M | -8.2x | --- |
ESSA Pharma Inc | 240.4M | -8.5x | --- |
Rezolute Inc | 240.5M | -4.1x | --- |
Zura Bio Ltd | 240.3M | -2.4x | --- |
Gossamer Bio Inc | 246.6M | -1.1x | --- |
Tectonic Therapeutic Inc | 250.5M | 2.1x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $243.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
